Taltobulin

• UNSPSC Description:

  Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1].

• Target Antigen:

  ADC Cytotoxin; Apoptosis; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/taltobulin.html

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC(C)(C)[C@H](NC([C@H](C(C)(C1=CC=CC=C1)C)NC)=O)C(N([C@@H](C(C)C)/C=C(C(O)=O)\C)C)=O

• Molecular Weight:

  473.65

• References & Citations:

  [1]Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63(8):1838-45.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 1

• CAS Number:

  228266-40-8